Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 120-129

  Vermeer, Daniel W ^a   Spanos, William C ^a,b   Vermeer, Paola D ^a   Bruns, Annie M ^c   Lee, Kimberly M ^a   Lee, John H ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Sanford Health ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CD47; HNSCC; HPV; immune; OSCC; radiation

Indexed keywords

CD47 ANTIGEN; CISPLATIN; GAMMA INTERFERON; GRANZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EPITHELIUM TUMOR; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RADIATION EXPOSURE; WART VIRUS;

ANIMALS; ANTIGENS, CD47; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, RADIATION; GRANZYMES; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON-GAMMA; MALE; MICE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PHAGOCYTOSIS; RADIOTHERAPY, ADJUVANT;

EID: 84876692703     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28015     Document Type: Article

References (50)

1. Prince A, Aguirre-Ghizo J, Genden E, et al. Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med 2010; 77: 684-99.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH,. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
3. Kamangar F, Dores GM, Anderson WF,. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
4. Kim L, King T, Agulnik M,. Head and neck cancer: changing epidemiology and public health implications. Oncology (Williston Park) 2010; 24: 915-9, 24.
5. Mendonca MS, Chin-Sinex H, Dhaemers R, et al. Differential mechanisms of x-ray-induced cell death in human endothelial progenitor cells isolated from cord blood and adults. Radiat Res 2011; 176: 208-16.
6. Karar J, Maity A,. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 2009; 8: 1994-2001.
7. Williams JR, Zhang Y, Zhou H, et al. Tumor response to radiotherapy is dependent on genotype-associated mechanisms in vitro and in vivo. Radiat Oncol 2010; 5: 71.
8. Demaria S, Formenti SC,. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007; 83: 819-25.
9. Formenti SC, Demaria S,. Local control by radiotherapy: is that all there is ? Breast Cancer Res 2008; 10: 215.
10. Ferrara TA, Hodge JW, Gulley JL,. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 2009; 11: 37-42.
11. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 1137-46.
12. Williams R, Lee DW, Elzey BD, et al. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 2009; 31: 911-8.
13. Martins I, Kepp O, Schlemmer F, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-58.
14. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
15. Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71.
16. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
17. Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 2011; 93: 294-300.
18. Seliger B,. Strategies of tumor immune evasion. BioDrugs 2005; 19: 347-54.
19. Garrido F, Algarra I, Garcia-Lora AM,. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother 2010; 59: 1601-6.
20. Algarra I, Garcia-Lora A, Cabrera T, et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 904-10.
21. Garrido F, Algarra I,. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117-58.
22. Hamai A, Benlalam H, Meslin F, et al. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 2010; 75: 1-8.
23. Shiao SL, Coussens LM,. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010; 15: 411-21.
24. van den Berg TK,. On the origin and function of immune 'self' recognition. Immunol Lett 2010; 128: 24-5.
25. Sarfati M, Fortin G, Raymond M, et al. CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr Drug Targets 2008; 9: 842-50.
26. Brown EJ, Frazier WA,. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001; 11: 130-5.
27. Latour S, Tanaka H, Demeure C, et al. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J Immunol 2001; 167: 2547-54.
28. Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 2009; 19: 72-80.
29. Suhr ML, Dysvik B, Bruland O, et al. Gene expression profile of oral squamous cell carcinomas from Sri Lankan betel quid users. Oncol Rep 2007; 18: 1061-75.
30. Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 2012; 28: 465-72.
31. Spanos WC, Geiger J, Anderson ME, et al. Deletion of the PDZ motif of HPV16 E6 preventing immortalization and anchorage-independent growth in human tonsil epithelial cells. Head Neck 2008; 30: 139-47.
32. Hoover AC, Spanos WC, Harris GF, et al. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg 2007; 133: 495-502.
33. Spanos WC, Hoover A, Harris GF, et al. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage- independent growth and synergizes with ras for invasive growth. J Virol 2008; 82: 2493-500.
34. Brenner JC, Graham MP, Kumar B, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010; 32: 417-26.
35. Matheu MP, Sen D, Cahalan MD, et al. Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging. J Vis Exp 2008; 17: 773.
36. Yamamoto Y, Usui F, Nakamura Y, et al. A novel method to isolate primordial germ cells and its use for the generation of germline chimeras in chicken. Biol Reprod 2007; 77: 115-9.
37. Lee DW, Anderson ME, Wu S, et al. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus- positive cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 1316-23.
38. Fucikova J, Kralikova P, Fialova A, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821-33.
39. Spisek R, Dhodapkar MV,. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 2007; 6: 1962-5.
40. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
41. Gardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123: 321-34.
42. Tsai RK, Discher DE,. Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008; 180: 989-1003.
43. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138: 271-85.
44. Jiang P, Lagenaur CF, Narayanan V,. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 1999; 274: 559-62.
45. Shafer-Weaver K, Sayers T, Strobl S, et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 2003; 1: 14.
46. Kim MJ, Lee JC, Lee JJ, et al. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 2008; 29: 28-34.
47. Chao MP, Tang C, Pachynski RK, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011; 118: 4890-901.
48. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 2009; 1: 3ra7.
49. Fontana MF, Vance RE,. Two signal models in innate immunity. Immunol Rev 2011; 243: 26-39.
50. Nair P, Amsen D, Blander JM,. Co-ordination of incoming and outgoing traffic in antigen-presenting cells by pattern recognition receptors and T cells. Traffic 2011; 12: 1669-76.